Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634357 · ClinicalTrials.gov registry record · Phase 1
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
A Phase 1 study of Liver Cancer and Hepatocellular Carcinoma (HCC), sponsored by Eureka Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT04634357: Recruiting Phase 1 study of Liver Cancer and Hepatocellular Carcinoma (HCC), sponsored by Eureka Therapeutics.
NCT04634357 is a Phase 1 study of Liver Cancer and Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by Eureka Therapeutics. The registered enrollment target is 15 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04634357, a Phase 1 study of Liver Cancer and Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by Eureka Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
Primary Outcome
Safety of ET140203 T cells as assessed by the number of adverse events (AEs) after infusion
Conditions Studied
Interventions
- DRUG ET140203 T Cells
Study Locations (2)
California
- UCSF Benioff Children's Hospitals - San Francisco
Massachusetts
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-07-19 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 1 |
What NCT04634357 shows while recruiting
NCT04634357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (97% lower).
The record links to 6 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which ET140203 T Cells is the first listed.
NCT04634357 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04634357 about?
NCT04634357 is a clinical study titled "ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma". Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
What is the current status of trial NCT04634357?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-07-19. Estimated completion is 2028-01-31.
What conditions does trial NCT04634357 study?
This clinical trial studies the following conditions: Liver Cancer, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Hepatoblastoma, Metastatic Liver Cancer.
What interventions are being tested in trial NCT04634357?
The interventions under investigation include: ET140203 T Cells (DRUG).
Who is sponsoring clinical trial NCT04634357?
This trial is sponsored by Eureka Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04634357 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04634357's enrollment target sits among peer trials
15 70th of 78 higher than 8 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
ACTIVE NOT RECRUITING · Phase 1
-
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI